Citação norma APA

Kazandjian, D., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S., & Pazdur, R. (2016). Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. Oncologist.

Citação norma Chicago

Kazandjian, Dickran, Gideon M. Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven Lemery, and Richard Pazdur. "Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer." Oncologist 2016.

Citação norma MLA

Kazandjian, Dickran, et al. "Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer." Oncologist 2016.

Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.